Illumina, Inc. has announced the introduction of the Infinium HumanLinkage-12 Genotyping BeadChip, Illumina’s fifth multi-sample Infinium BeadChip and the Company’s first standard panel to take ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today launched an advanced high-throughput screening (HTS) array format that significantly increases the number of samples that can be ...

Illumina, Inc. (NASDAQ:ILMN) today announced its next generation of iSelect custom genotyping products that allow researchers to design custom arrays containing from 3,000 up to 1,000,000 markers, ...

Illumina, Inc. (NASDAQ:ILMN) today unveiled its new HumanOmniExpress+ Custom BeadChip (OmniExpress+), an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up ...

Using SNP-CGH to Profile for Amplifications, Duplications, and Deletions The beginnings of personalized medicine have been forged by recent advances in SNP genotyping technologies. It is now possible ...

Illumina will see expanded use of its technologies in China through a new partnership with a Chinese provider of diagnostic testing services used by hospitals and physicians in every province of the ...

Illumina, Inc. (NASDAQ: ILMN) announced today that it has signed a multi-phase genotyping services agreement to support colorectal cancer researchers funded by Cancer Research UK, the world’s leading ...